

Fig. S6. Enoxacin potently enhances RNAi response by promoting RISC activity.

a, Fluorescent images of 293T-EGFP cells in the absence or presence of enoxacin (50 μM) are shown on the left. Cells treated with EGFP-shRNA or EGFP-shRNA plus enoxacin are shown in the middle panels. Cells treated with 10 μM EGFP-siRNA or EGFP-siRNA plus enoxacin are shown in the right panels. The $EGFP^+$ cells were quantified and cells treated with DMSO was defined as 100%. Scale bar, 100 μm. All data are shown as means ± SD, one-way ANOVA, ## $p<0.01$, **** $p<0.0001$. **b,** Northern blots of EGFP-siRNA in 293T cells, in which cells were treated with DMSO, enoxacin, EGFP-shRNA, or EGFP-shRNA together with enoxacin. The treatment with enoxacin did not promote the production of EGFP-siRNA from EGFP-shRNA. siRNA

production was quantified and cells treated with shRNA was defined as 1. All data are shown as means ± SD, t test. U6 was used as the internal reference (Supplementary Table 4).